Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- IMPL
- Price
- -
- Stock movement down
- -0.00 (-21.50%)
- Company name
- Impel Neuropharma Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Market cap
- 375.23K
- Ent value
- 127.11M
- Price/Sales
- 0.02
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -0.10%
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -99.32%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2024-12-17
DIVIDENDS
IMPL does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 0.02 |
| Price to Book | - |
| EV to Sales | 6.06 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 23.90M |
| EPS (TTM) | -4.05 |
| FCF per share (TTM) | -3.46 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 20.99M |
| Gross profit (TTM) | 11.04M |
| Operating income (TTM) | -70.11M |
| Net income (TTM) | -96.11M |
| EPS (TTM) | -4.05 |
| EPS (1y forward) | -0.87 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 52.58% |
| Operating margin (TTM) | -334.06% |
| Profit margin (TTM) | -457.97% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 239.00K |
| Net receivables | 6.59M |
| Total current assets | 23.43M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 7.82M |
| Total assets | 35.07M |
| Accounts payable | 3.73M |
| Short/Current long term debt | 114.80M |
| Total current liabilities | 124.74M |
| Total liabilities | 126.98M |
| Shareholder's equity | -91.91M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -79.09M |
| Capital expenditures (TTM) | 3.15M |
| Free cash flow (TTM) | -82.24M |
| Dividends paid (TTM) | 79.00K |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -274.04% |
| Return on Invested Capital | -465.26% |
| Cash Return on Invested Capital | -398.10% |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| IMPL | S&P500 | |
| Current price drop from All-time high | -99.94% | -0.50% |
| Highest price drop | -99.96% | -56.47% |
| Date of highest drop | 12 Feb 2024 | 9 Mar 2009 |
| Avg drop from high | -74.53% | -11.07% |
| Avg time to new high | 102 days | 12 days |
| Max time to new high | 636 days | 1805 days |
COMPANY DETAILS
Marketcap
375.23K
Marketcap category
Small-cap
Description
Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. The company was incorporated in 2008 and is headquartered in Seattle, Washington. On December 19, 2023, Impel Pharmaceuticals Inc, along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of Texas.
Employees
160
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner